cardiovascular-agents and imperatorin

cardiovascular-agents has been researched along with imperatorin* in 3 studies

Reviews

1 review(s) available for cardiovascular-agents and imperatorin

ArticleYear
Effects of imperatorin in the cardiovascular system and cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 120

    Patients with cancer survivors are at increased risk of cardiovascular disease(CVD). Cardio-oncology has developed as a new discipline with the advances in cancer treatment. There are many new challenges for the clinician and a new frontier for research and investigation. There is an urgent need for further study on the prevention of cardiovascular toxicity. Imperatorin (IMP) is a natural form of coumarin and extract from several plants with diver's pharmacokinetic effects, including antioxidant and anti-inflammatory properties. This review focus on the molecular mechanisms and pharmacological effects of Imperatorin maybe provide potential cancer and cardiovascular protection that targets IMP. Further studies are required to elucidate the entire spectrum of cytotoxic activities of these compounds to validate and expand their preclinical and clinical applications and to clarify the potential role of IMP.

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Cardiovascular Agents; Cardiovascular Diseases; Cardiovascular System; Furocoumarins; Humans; Inflammation Mediators; Neoplasms; Oxidative Stress; Signal Transduction

2019

Other Studies

2 other study(ies) available for cardiovascular-agents and imperatorin

ArticleYear
Furanocoumarins-imperatorin inhibits myocardial hypertrophy both in vitro and in vivo.
    Fitoterapia, 2010, Volume: 81, Issue:8

    The furanocoumarin imperatorin has been reported to have hypotensive effect, and we have investigated its activity on myocardial hypertrophy. Imperatorin displayed similar chromatographic retention peak to verapamil in the model of cardiac muscle/cell membrane chromatography, and could reduce in a concentration-dependent way protein content and cell size of myocytes prestimulated with angiotensin II. The ratio of heart weight to body weight (mg/g) (4.13 ± 0.06 in SHRs, 3.77 ± 0.02 with imperatorin 25 mg kg(-1)d(-1) 16 17 ig, P<0.01) was significantly lower in the imperatorin-treated SHRs. Taken together, our observations show that imperatorin exerts anti-hypertrophic effect both in vitro and in vivo.

    Topics: Angiotensin II; Animals; Cardiomegaly; Cardiovascular Agents; Cells, Cultured; Furocoumarins; Heart Failure; Molecular Structure; Myocardium; Myocytes, Cardiac; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley

2010
[Some pharmacological data on the action of imperatorin].
    Farmatsevtychnyi zhurnal, 1962, Volume: 17(6)

    Topics: Cardiovascular Agents; Furocoumarins; Khellin; Muscle Relaxants, Central

1962